You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 7,009,037

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,009,037

Title:	Modified HIV-1gag p17 peptide and immunogenic composition
Abstract:	The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p17 and p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
Inventor(s):	Sorensen; Birger (Skien, NO)
Assignee:	Bionor Immuno AS (Gulset, NO)
Application Number:	10/129,331
Patent Claims:	1. An isolated HIV-1 gag p17 peptide comprising the amino acid sequence of SEQ ID NO: 3, wherein the terminal ends of the sequence may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof and/or the sequence is immobilized to a solid support. 2. An antigen comprising at least one peptide according to claim 1. 3. An immunogenic composition comprising the antigen according to claim 2 with a pharmaceutically acceptable diluent and optionally an adjuvant, carrier and/or vehicle and optionally additional immunostimulatory compound(s). 4. The immunogenic composition according to claim 3, wherein the antigen comprises the peptides of the SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 11 and SEQ ID NO: 14. 5. The immunogenic composition according to claim 3, wherein the antigen comprises peptides that are dissolved in a sterile water solution and the optional immunostimulatory compound is a granulocyte macrophage colony stimulating factor. 6. The immunogenic composition according to claim 3, wherein the composition comprises an adjuvant selected from the group consisting of Monophosphoryl Lipid A (MPL.RTM.), Freund's complete adjuvant, Freund's incomplete adjuvant and aluminum hydroxide. 7. The immunogenic composition according to claim 2, wherein the antigen is formulated as a lipopeptide and/or a liposome formulation.

Details for Patent 7,009,037

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2020-09-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.